Literature DB >> 1744582

Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.

D L Jicha1, J J Mulé, S A Rosenberg.   

Abstract

Interleukin 7 (IL-7) is a 25-kD cytokine that was initially described as a pre-B cell growth factor. This cytokine has also been shown to have T cell proliferative and differentiation effects. In this report, we demonstrate that antitumor cytotoxic T lymphocytes (CTL) generated by secondary in vitro sensitization of draining lymph node cells in IL-7 are effective in treating 3-day syngeneic methylcholanthrene (MCA) sarcoma pulmonary metastases in mice. In vivo titrations comparing IL-7 to IL-2 antitumor CTL show that they have equivalent potency in adoptive immunotherapy. IL-7 antitumor CTL generated against MCA sarcomas of weak immunogeneity are also tumor specific in their in vivo efficacy. This study represents the first successful use of a cytokine other than IL-2 for the generation of cells with in vivo efficacy in cellular adoptive transfer.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744582      PMCID: PMC2119035          DOI: 10.1084/jem.174.6.1511

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Effect of IL-7 on the growth of fetal thymocytes in culture.

Authors:  J D Watson; P J Morrissey; A E Namen; P J Conlon; M B Widmer
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

2.  Murine thymocytes proliferate in direct response to interleukin-7.

Authors:  P J Conlon; P J Morrissey; R P Nordan; K H Grabstein; K S Prickett; S G Reed; R Goodwin; D Cosman; A E Namen
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

3.  Interleukin 7 is a T-cell growth factor.

Authors:  G D Chazen; G M Pereira; G LeGros; S Gillis; E M Shevach
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

4.  Stimulation of B-cell progenitors by cloned murine interleukin-7.

Authors:  A E Namen; S Lupton; K Hjerrild; J Wignall; D Y Mochizuki; A Schmierer; B Mosley; C J March; D Urdal; S Gillis
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

5.  Characterization of a novel murine T cell-activating factor.

Authors:  R D Garman; D H Raulet
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

6.  Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy.

Authors:  S Y Shu; T Chou; S A Rosenberg
Journal:  J Immunol       Date:  1987-07-01       Impact factor: 5.422

7.  Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells.

Authors:  R G Goodwin; S Lupton; A Schmierer; K J Hjerrild; R Jerzy; W Clevenger; S Gillis; D Cosman; A E Namen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

8.  T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor.

Authors:  C Uyttenhove; P G Coulie; J Van Snick
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

9.  B cell precursor growth-promoting activity. Purification and characterization of a growth factor active on lymphocyte precursors.

Authors:  A E Namen; A E Schmierer; C J March; R W Overell; L S Park; D L Urdal; D Y Mochizuki
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cells.

Authors:  P J Morrissey; R G Goodwin; R P Nordan; D Anderson; K H Grabstein; D Cosman; J Sims; S Lupton; B Acres; S G Reed
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  33 in total

1.  Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.

Authors:  Asa Andersson; Minu K Srivastava; Marni Harris-White; Min Huang; Li Zhu; David Elashoff; Robert M Strieter; Steven M Dubinett; Sherven Sharma
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Interleukin-7 in the skin of Schistosoma mansoni-infected mice is associated with a decrease in interferon-gamma production and leads to an aggravation of the disease.

Authors:  I Wolowczuk; M Delacre; O Roye; S L Giannini; C Auriault
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

Review 3.  Gene therapy in pediatric oncology.

Authors:  E Benaim; B P Sorrentino
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Authors:  Devin B Lowe; Michael H Shearer; Cynthia A Jumper; Robert K Bright; Ronald C Kennedy
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

5.  Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.

Authors:  M Wang; P W Chen; V Bronte; S A Rosenberg; N P Restifo
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-10

6.  IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Authors:  G Ferrari; K King; K Rathbun; C A Place; M V Packard; J A Bartlett; D P Bolognesi; K J Weinhold
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

7.  Stimulation of B-cell lymphopoiesis by interleukin-7 leads to aggravation of murine leishmaniasis.

Authors:  A Gessner; A Will; M Vieth; K Schröppel; M Röllinghoff
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

8.  Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.

Authors:  W J Murphy; T C Back; K C Conlon; K L Komschlies; J R Ortaldo; T J Sayers; R H Wiltrout; D L Longo
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Antitumor effect of mSurvivinThr34→Ala in murine colon carcinoma when administered intravenously.

Authors:  Hong-xia Li; Xin-yu Zhao; Lian Wang; Yong-sheng Wang; Bin Kan; Jian-rong Xu; Jiong Li; Yan-Jun Wen; Xing-chen Peng; Xiang Chen; Fei Yan; Bin Ye; Xiao-bo Du; Ju-mei Zhao; Tao Yi; Xian-cheng Chen; Xiao-xia Du; Yu-quan Wei; Xia Zhao
Journal:  Med Oncol       Date:  2009-12-01       Impact factor: 3.064

10.  Measurement of cytotoxic activity in experimental cancer.

Authors:  Nayara Delgado Andre; Décio Sabbatini Barbosa; Egberto Munhoz; Dirceu Estevão; Rubens Cecchini; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.